Neurocrine Biosciences
NBIX
#1585
Rank
NZ$22.53 B
Marketcap
NZ$226.00
Share price
-1.38%
Change (1 day)
-16.14%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): NZ$7.40

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$7.16. In 2024 the company made an earnings per share (EPS) of NZ$5.61 an increase over its 2023 EPS that were of NZ$4.22.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$7.4031.76%
2024NZ$5.6133.07%
2023NZ$4.2257.76%
2022NZ$2.6769.47%
2021NZ$1.58-78.21%
2020NZ$7.24990%
2019NZ$0.6681.82%
2018NZ$0.37-113.5%
2017NZ-$2.710.62%
2016NZ-$2.6957.28%
2015NZ-$1.7125.61%
2014NZ-$1.3618.84%
2013NZ-$1.15-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.86-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.25-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$34.08 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$0.04983-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.37-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.84-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$49.66-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.93-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK